Monocytosis Subsequent to Ziprasidone Treatment: A Possible Side Effect

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Ziprasidone is an atypical antipsychotic agent that is available as oral and short-acting intramuscular formulations and is approved by the U.S. Food and Drug Administration for management of schizophrenia and bipolar disorder. Ziprasidone acts as a serotonin and dopamine receptor antagonist, with greater affinity for the 5-HT2A receptor than the dopamine D2 receptor.1 Moreover, it possesses agonist activity at the serotonin 5-HT1A receptor.1

Prim Care Companion J Clin Psychiatry 2007;9(6):465-466 [letter]

https://doi.org/10.4088/PCC.v09n0611b